Consolidated Statement of Stockholders' Equity (unaudited) - 3 months ended Dec. 31, 2016 - USD ($)	Total	Amgen	Preferred Stock	Common Stock	Common Stock Amgen	Additional Paid-In Capital	Additional Paid-In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2016	$ 95,024,259		$ 16	$ 162,116		$ 493,844,909		$ 7,449	$ (398,435,043)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2016			15,652	69,746,685
Stock-based compensation	2,424,442					2,424,442
Common stock- Restricted Stock Units vesting, Amount	(381,564)			$ 249		(381,813)
Common stock- Restricted Stock Units vesting, Shares				249,556
Stock issuances		$ 12,420,000			$ 1,746		$ 12,418,254
Stock issuances, Shares					1,745,810
Preferred stock converted to common stock, Amount			$ (16)	$ 2,671		(2,655)
Preferred stock converted to common stock, Shares			(15,652)	2,670,989
Foreign currency translation adjustments	(192,608)							(192,608)
Net loss	(12,086,108)								(12,086,108)
Ending Balance, Amount at Dec. 31, 2016	$ 97,208,421			$ 166,782		$ 508,303,137		$ (185,159)	$ (410,521,151)	$ (555,188)
Ending Balance, Shares at Dec. 31, 2016				74,413,040